Etabenzarone is an anti-inflammatory and anticoagulant agent.

Estrapronicate is a synthetic estrogen exerting anabolic properties.

Droxicainide is a new antiarrhythmic agent. When given intravenously droxicainide suppressed ouabain-induced arrhythmias in pentobarbital-anesthetized guinea pigs. The initial experimental studies reported that droxicainide appears to have a more potent antiarrhythmic activity and fewer side effects than lidocaine. In local anesthetic tests and following intradermal administration to rabbits, droxicainide produced less local tissue irritation than lidocaine. Droxicainide is a class 1 anti-arrhythmic drug.

FLUMEXADOL is a non-opioid analgesic. Its prodrug OXAFLOZANE was used as an antidepressant in France till 2004.

Indanidine is a selective and effective α2-antagonist, α1-partial agonist patented by pharmaceutical company Siegfried A.-G as a low toxic compound with direct hypotensive action. Indanidine does not penetrate the blood-brain barrier, does not induce drug-metabolizing enzymes in the liver, does not cause behavioral changes.

Pipramadol is an analgesic agent. Pipramadol exhibits not only antinociceptive but also central and peripheral antiserotonin properties.

Lorcinadol is an analgesic agent.

Quinezamide is a pyrazolo[1,5-c]quinazoline derivative patented by E. Gy. T. Gyogyszervegyeszeti Gyar, Hung as antiulcerogenic compound.

Ragaglitazar (DRF 2725, NNC 61-0029) is phenoxazine analog of phenyl propanoic acid having dual (PPARα and PPARγ) agonist property intended to restore insulin sensitivity and correct diabetic dyslipidemia. PPAR-α is highly expressed in liver and muscle and upon activation leads to decreases in plasma triglycerides and increases in HDL cholesterol levels. PPAR-γ activation leads to enhancement of glucose uptake in skeletal muscles and adipose tissue. Ragaglitazar provided the glycemic control that was comparable with that of pioglitazone and, compared with placebo, provided a significant improvement in the lipid profile.

Ramixotidine (also known as CM 57755 ) is a nicotinamide 1-oxide derivative patented by Sanofi as a gastric antisecretory agent. Ramixotidine is competitive histamine H2-receptor antagonist, that inhibits histamine-induced gastric acid secretion. In preclinical studies, Ramixotidine caused inhibition of dimaprit- or pentagastrin-induced secretion. Acid secretion stimulated by a meat meal was significantly reduced by Ramixotidine Ramixotidine appears to be an inhibitor of gastric acid secretion induced by different stimulants in dogs with a potency comparable to cimetidine. Unfortunately, in clinical trials, Ramixotidine failed to demonstrate efficacy and further development was discontinued.